- AU$22.59m
- AU$26.83m
- AU$12.46m
Australia's Althea rises on pharma asset sale, focus on North American operations
Brief: Althea Group Holdings Announces Sale Of Pharmaceutical Assets For A$1 Million To Tasmanian Botanics
Brief: Althea Group Announces Withdrawal Of FY25 Guidance
Brief: Althea Group Secures A$4.0 Million To Rapidly Scale THC Beverage Growth In North America
Brief: Althea Group Sees FY Positive Adjusted EBITDA A$0.8 Million To A$1.1 Million
Brief: Althea Group Holdings Seeks Trading Halt
Brief: Althea Group To Receive A$2 MLN In Funding
Brief: Althea Group Says Termination Of CFO Robert Meissner
Brief: Althea Group Holdings Seeks Trading Halt
Brief: Althea Group Says Peak To Launch Two Cannabis-Infused Beverages For Simply Solventless
Brief: Althea Group Posts Revenue Of A$8.3 Mln (Unaudited) For Quarter
Brief: Althea Group Sells Myaccess Clinics To Montu Group UK
Brief: Althea Group Posts Loss For Year Attributable A$32.1 Mln
Brief: Althea Group Says Vaughan Webber To Assume Role Of Chairman
Brief: Althea Group Says FY25 Guidance In Range Of A$50 Million To A$60 Million In Revenue
Brief: Althea Group Says U.S. Cannabis Beverages Joint Venture Agreements Executed
Australia's Althea Group eyes worst day in 2 yrs on discounted placement
Brief: Althea Group Completes A$2.0 Million Placement
Brief: Althea Group Seeks Trading Halt